Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genocea Biosciences (GNCA)

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

Additional positive GEN-009 clinical immunogenicity data driven by ATLAS(TM) to be presented at ESMO

GNCA : 2.69 (+0.37%)
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 93.75 (+0.28%)
GNCA : 2.69 (+0.37%)
REPH : 11.77 (+2.17%)
ZTS : 127.93 (-0.61%)
CPRX : 5.22 (-0.85%)
FLXN : 14.04 (-0.78%)
VRCA : 14.60 (-5.07%)
Genocea to Present at September Healthcare Conferences

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present...

GNCA : 2.69 (+0.37%)
Genocea Biosciences: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $6.5 million in its second quarter.

GNCA : 2.69 (+0.37%)
Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results

Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009;

GNCA : 2.69 (+0.37%)
Genocea to Host Quarterly Corporate Update Conference Call & Webcast on July 25th at 8:30 am ET

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its second-quarter 2019 financial results and corporate update conference...

GNCA : 2.69 (+0.37%)
Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019

Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading U.S. and...

TCDA : 33.59 (+1.94%)
INSM : 17.56 (+0.46%)
AVEO : 0.92 (+11.84%)
GNCA : 2.69 (+0.37%)
MYOV : 5.46 (+2.06%)
AQ : 13.24 (unch)
MRVL : 23.78 (-2.54%)
VICL : 0.68 (-15.68%)
PINS : 25.74 (+0.66%)
TMDX : 17.90 (+0.51%)
FSLY : 22.32 (-4.37%)
HTGC : 13.45 (+0.37%)
HCXZ : 25.89 (+0.62%)
HCXY : 25.95 (-0.88%)
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing of its previously announced underwritten public offering...

GNCA : 2.69 (+0.37%)
Thinking about buying stock in Aurora Cannabis, Cypress Semiconductor, Delmar Pharmaceuticals, Genocea Biosciences, or Stellar Biotech?

InvestorsObserver issues critical PriceWatch Alerts for ACB, CY, DMPI, GNCA, and SBOT.

ACBFF : 8.6900 (-12.80%)
CY : 23.38 (unch)
GNCA : 2.69 (+0.37%)
Thinking about buying stock in Avon Products, Genocea Biosciences, L Brands, Netshoes, or Obalon Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for AVP, GNCA, LB, NETS, and OBLN.

AVP : 4.13 (-0.24%)
GNCA : 2.69 (+0.37%)
LB : 17.81 (-0.45%)
NETS : 3.70 (-2.63%)
OBLN : 1.84 (+6.98%)
Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EYEG, FATE, FGEN, and GNCA which can be accessed for free by signing up to www.wallstequities.com/registration....

EYEG : 3.37 (-3.71%)
FATE : 14.54 (-1.42%)
FGEN : 40.30 (+3.71%)
GNCA : 2.69 (+0.37%)
Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess...

GNCA : 2.69 (+0.37%)
Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial

Post-vaccination immune responses detected to 93% of vaccine neoantigens

GNCA : 2.69 (+0.37%)
Detailed Research: Economic Perspectives on CAI International, Genocea Biosciences, RF Industries, and Bilibili Inc. Sponsored ADR -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CAI International, Inc. (NYSE:CAI),...

CAI : 21.78 (-0.05%)
GNCA : 2.69 (+0.37%)
RFIL : 6.59 (+0.46%)
BILI : 14.56 (+0.34%)
Genocea Biosciences: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Tuesday reported a loss of $15.6 million in its first quarter.

GNCA : 2.69 (+0.37%)
Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its first-quarter 2019 financial results and corporate update conference...

GNCA : 2.69 (+0.37%)
Genocea to Present at 18th Annual Needham Healthcare Conference

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present...

GNCA : 2.69 (+0.37%)
Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS(TM) Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data from ATLAS(TM), its ex vivo platform for comprehensively...

GNCA : 2.69 (+0.37%)
Top Ranked Momentum Stocks to Buy for March 20th

Top Ranked Momentum Stocks to Buy for March 20th

SIC : 11.56 (+2.48%)
RDY : 38.13 (-0.16%)
GNCA : 2.69 (+0.37%)
CLAR : 12.13 (+5.11%)
Will Genocea Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Genocea Biosciences.

GNCA : 2.69 (+0.37%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.04 , AIZ -0.01 , SBAC -6.07 , SO +0.39 , WELL -0.37
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar